Alan Cassels is a drug policy researcher affiliated with the Faculty of Human and Social Development at the University of Victoria, British Columbia, Canada
- 1-250-361 3120
Research suggests no substantive outcome differences between the use of originator biologics and their biosimilar counterparts Source: Shutterstock.com There is sufficient evidence to pro
Although PCSK9 inhibitors have been hailed as the next big thing in the treatment of high cholesterol, there are not enough data to make informed opinions about their overall value.
Why sprinting to change clinical practice guidelines on blood pressure treatment is prematureSubscription
Caution is required when the media reports on high profile medical studies.